On August 25, BeiGene fell 0.57%, with trading volume of RMB 968 million, turnover rate of 3.04%, and total market value of RMB 424.283 billion.
Price movement analysis
Benefiting from innovative drugs + RMB depreciation
1. On June 13, 2025, in an interaction on Yi YI: The company is a globally leading innovative oncology treatment company. It develops innovative anti-cancer drugs for cancer patients worldwide, improving drug accessibility and affordability.
2. According to the 2024 annual report, the company’s overseas revenue accounted for 62.85%, benefiting from RMB depreciation.
(Disclaimer: The analysis content is sourced from the internet and does not constitute investment advice. Investors should make independent judgments based on different market conditions.)
Capital Analysis
Today's major net inflow was 20.7742 million yuan, accounting for 0.02%, ranking 16/157 in the industry. The stock currently shows no continuous accumulation or reduction of holdings, and the major-player trend is not obvious; the industry's major net inflow was 957 million yuan, and there is currently no continuous accumulation or reduction of holdings, so the major-player trend is not obvious.
Range Today Last 3 Days Last 5 Days Last 10 Days Last 20 Days Major Net Inflow 20.7742 million -353 million -195 million -747 million -661 million Major Holdings
The major player has not controlled the market; chip distribution is very dispersed. The major player's trading volume was 696 million yuan, accounting for 9.61% of the total trading volume.
Technical analysis: average trading cost of holdings is 280.62 yuan
The average trading cost of this stock's shares is 280.62 yuan. Recently, holdings have been reduced, but the pace of reduction has slowed. The current share price is close to the resistance level of 276.01, so be cautious of a pullback at the resistance level. If it breaks through the resistance level, it may start an upward trend.
Company Profile
According to information, BeiGene Co., Ltd. is located at No. 30, Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing. It was established on October 28, 2010 and listed on December 15, 2021. The company's main business involves the research, development, production, and commercialization of innovative drugs. The revenue composition of its main business is: anti-tumor drugs 98.81%, drug collaboration arrangement income 1.19%.
BeiGene belongs to the Shenwan industry: Pharmaceuticals & Biotechnology - Chemical Pharmaceuticals - Chemical Preparations. Related concept sectors include: innovative drugs, biopharmaceuticals, Healthy China, Going Global 50, Shanghai-Hong Kong Stock Connect, etc.
As of March 31, BeiGene had 35,400 shareholders, up 6.50% from the previous period. Circulating shares per capita were 3,265 shares, down 6.13% from the previous period. From January to March 2026, BeiGene achieved operating revenue of 10.544 billion yuan, up 31.02% year on year; net profit attributable to shareholders was 1.608 billion yuan, up 1801.30% year on year.
In terms of institutional holdings, as of March 31, 2026, among BeiGene's top 10 circulating shareholders, Hong Kong Securities Clearing Company Limited ranked as the fourth-largest circulating shareholder, holding 2.970 million shares, a decrease of 459,100 shares from the previous period. Wanjia Select (161903) ranked as the sixth-largest circulating shareholder, holding 2.000 million shares, unchanged from the previous period. Yongying Pharmaceutical Innovation Smart Select Mixed Initiation A (015915) ranked as the seventh-largest circulating shareholder, holding 1.9704 million shares, a decrease of 29,000 shares from the previous period. China Europe Healthcare Balanced A (003095) ranked as the eighth-largest circulating shareholder, holding 1.8127 million shares, a decrease of 2.2996 million shares from the previous period. ICBC Frontier Medical Stock A (001717) ranked as the tenth-largest circulating shareholder, holding 1.800 million shares, a decrease of 200,000 shares from the previous period. Southern CSI 500 ETF (510500) fell out of the top 10 circulating shareholders.
Disclaimer: The market involves risks, so investments should be made cautiously. This article is published based on a third-party database and does not represent the views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. In case of any discrepancy, please refer to the actual announcement. If you have any questions, please contact biz@staff.sina.com.cn.